Skip to content

Pain Processing in Adults With Migraines

Pain Processing in Adults With Migraines

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02748577
Enrollment
121
Registered
2016-04-22
Start date
2016-08-24
Completion date
2019-07-16
Last updated
2020-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraines

Keywords

Migraines, Pain responses

Brief summary

Primary Objective of this study: To assess experimental heat pain responses (pain intensity, pain unpleasantness, pain catastrophizing, emotional reactivity) in migraineurs vs. healthy controls. The current tools of migraine pain measurement are inadequate to distinguish the overall burden of suffering, as there is an over reliance on a single numerical pain score to represent the entire pain experience. Measuring and targeting the affective component, in addition to the sensory component of pain, may capture this discrepancy in disease burden. The affective component of migraine pain may be just as important as the sensory component to target and measure since it significantly impacts outcomes, disability, and has therapeutic treatment implications. Quantitative sensory testing (QST) is a robust lab paradigm (not a clinical experience) that delivers one painful noxious thermal stimuli and asks for simultaneous pain intensity and pain unpleasantness scores. By using this in the research, investigators will be able to differentiate the sensory (pain quality-what the pain feels like) from the affective (how awful/unpleasant the pain feels) components of experimental pain in normal controls vs. migrainuers. No previous studies have evaluated differences in experimental pain intensity vs. pain unpleasantness in migraineurs vs. controls. As migraine pain uniquely involves many altered sensory phenomenon (e.g., photophobia, phonophobia), it cannot be assumed that responses to experimental pain in migraine will be the same as other clinical pain syndromes. Further, different clinical pain syndromes have distinct responses to pain intensity vs. pain unpleasantness.

Detailed description

Investigators will conduct a cross-sectional study in migraineurs (interictally, i.e., between migraine attacks) and healthy controls to compare responses to experimental heat pain intensity and unpleasantness and correlate these results to differences in emotional reactivity and pain catastrophizing.

Interventions

OTHERQuestionnaires

Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.

OTHERQuantitative Sensory Testing (QST) Pain Measurements

Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Inclusion criteria for Healthy Controls: * ≥18yo; 2. Inclusion Criteria for Migraineurs: * ≥18yo with \>1 yr of migraines and currently 4-20 days/month with migraines, although no migraine within 48 hrs of study visit.

Exclusion criteria

1. Any major unstable medical/psychiatric illness (e.g., hospitalization within 90 days, suicide risk, etc.) 2. Severe clinical depression/anxiety 3. Chronic pain condition (e.g., fibromyalgia, migraines for healthy controls, etc.) or sensory abnormalities (e.g., neuropathy, Raynaud's, etc.) 4. Diagnosis of medication overuse headache or chronic migraine. 5. Migraineurs will be studied after being headache-free for at least 48 hours (interictally). 6. Participants may be currently taking migraine medications, as long as they do not have a diagnosis of medication overuse headache. 7. Pregnant subjects will be excluded from all portions of the study due to possible unknown risks of frankly noxious stimuli. 8. Due to unknown risks and potential harm to the unborn fetus, sexually active women of childbearing potential must use a reliable method of birth control while participating in this study 9. Volunteers with no pain ratings to frankly noxious stimuli (temperatures \> 49°C) or excessive responses to threshold temperatures (\ 43°C)

Design outcomes

Primary

MeasureTime frameDescription
Heat Pain Intensity coefficient and intercept from stimulus response curveOne visitUsing the logarithmic equation: log (VAS pain ratings)=log (t - 35) \* coefficient + intercept where t represents stimulus temperature, we will generate stimulus-response curves for each subject
Heat Pain Unpleasantness coefficient and intercept from stimulus response curveOne visitUsing the logarithmic equation: log (VAS pain ratings)=log (t - 35) \* coefficient + intercept where t represents stimulus temperature, we will generate stimulus-response curves for each subject
Pain Catastophizing scoreOne VisitScore on the Pain Catastrophizing instrument
Difficulty in Emotions Regulation scoreOne VisitScore on the Difficulty in Emotions Regulation score

Secondary

MeasureTime frameDescription
Heat Pain Threshold TemperatureOne VisitTemperature of heat pain threshold
AnxietyOne VisitScore on the Generalized Anxiety Disorder (GAD-7) instrument
DepressionOne VisitScore on the Patient Health related questionnaire-depression module (PHQ-9) instrument
MindfulnessOne VisitScore on the Five Factor Mindfulness (FFM) instrument
OptimismOne VisitScore on the Life Orientation Test instrument
HopeOne VisitScore on the Herth Hope Index instrument
SleepOne VisitScore on the NIH Promis Measure of sleep disturbance instrument
Global HealthOne VisitScore on the 1st question of the NIH Promis Global Health measure
StressOne VisitScore on the Perceived Stress Scale (PSS) instrument
Social ConnectednessOne VisitScore on the Social Connectedness Scale instrument
FlourishingOne VisitScore on the Flourishing scale instrument
ResilienceOne VisitScore on the Brief Resilience scale instrument

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026